The rapid evolution in our understanding of lung cancer biology has led to a significant paradigm shift in the management of patients with non-small cell lung cancer. Elucidation of biologic mechanisms that underpin carcinogenetic potential and metastatic behavior has led to an inevitable explosion in the development of effective targeted agents, many of which have been proven to be more effective and less toxic therapeutic approaches.
Despite energetic efforts and the enormous support gained within the oncology community, there are many obstacles in the clinical implementation of precision medicine. On the one hand there is increasing pressure to utilize some form of biologic treatment or immunotherapy for each individual patient; on the other hand, the immense bulk and the rapid recycling of the new information complicates interpretation of the data when we are faced with the patient in our daily clinical practice. In fact, translation of the acquired knowledge from the lab bench to the bedside to develop an efficacious treatment has proved to be an extremely difficult task, owing to the existing gaps in our understanding of the biology of cancer coupled with contradictatory findings from clinical trials,
The success of five previous meetings and our willingness to extend collaboration through continents have prompted us to organize the 6thLung Cancer Network «Bridging Science and Practice». Our aim is to provide a comprehensive update of the accumulating evidence and to tease out the useful information from the background noise in order to optimize the use of “precision medicine” in the real-life setting by bringing together basic scientists, clinical researchers and lung cancer specialists who have contributed immensely to this field. Our distinguished multidisciplinary, international faculty will discuss the latest translational and clinical data to provide treating physicians with practical information on how to implement recent developments in their clinical practice.
Finally, we hope that this meeting will provide a great opportunity to all of us not only to improve collaboration for our future educational goals, but also to serve as a platform to develop great friendships in the long run.
We cordially welcome you all in the 6th Lung Cancer Network Symposium: Bridging Science and Practice, held in collaboration with the Turkish Association of Lung Cancer (TAKD) to take place in Istanbul between December 14-15, 2018.
The venue of the event, Swissotel the Bosphorus, is located on the coastal hills overlooking the Bosphorus in a very safe and upscale area of the city, with an amazing picturesque view.
At the end of our educational meeting, the participant will be able to:
- Recognize the clinical significance of molecular genotyping of lung cancer patients
- Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
- Update of Immunotherapy strategies for lung cancer
- Discuss the optimal methodology of evaluation of response in the era of translational research
- Recognize the importance of a multidisciplinary approach to the care of lung cancer patients
- Prevention and screening
- Prognostic and predictive tumor markers
- Optimal use of diagnostic material and techniques to guide in treatment decisions
- Update on driver oncogenes
- Changing algorithms with newer generation TKI’s
- Evolving field of immuno-oncology
- Integration of immunotherapy in daily practice
- Implementation of personalized treatment and immunotherapy in early stages
- Management of toxicity
- Recent advances in thoracic tumors beyond NSCLC
The meeting is designed for medical, radiation and surgical oncologists, pathologists, chest physicians, scientists, residents-in-training, fellows and other health care professionals interested in the basic and clinical research as well as in the management of thoracic cancers.
MD, Professor of Medical Oncology and Internal Medicine, Istanbul University,
Institute of Oncology, Istanbul, Turkey
MD, Professor of Medical Oncology and Internal Medicine, Ege University,
Tulay Aktas Oncology Hospital, İzmir, Turkey,
President Elect, Turkish Society of Lung Cancer (TAKD)
MD, PhD, Professor of Medicine and Pathology, Executive Director for the Clinical Lung Cancer Institute at Mount Sinai, New York, USA, Former CEO, International Association for the Study of Lung Cancer (IASLC), USA
***in alphabetical order
MD, PhD, FCCP, Professor of Medicine & Medical Oncology, Head,
3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, GR
Adj. Professor of Medicine, Pittsburgh School of Medicine, USA,
Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA